Director, Thought Leader Liaison, West Coast

Los Angeles, California (West Coast Preferred). Posted 11 months ago

The role

The Director, Thought Leader Liaison will lead field marketing efforts including Key Opinion Leader identification and management, Speaker Bureau Management, and local or regional Patient Advocacy Engagements. This role involves collaborating on marketing materials and engaging with healthcare professionals and patients.

What you will do

KOL Healthcare Provider Identification and Engagement
Market Insight Gathering on current disease management landscape
Speaker Bureau Management, including HCP Speaker Identification, Engagement and Training and HCP Speaker Bureau Content Creation
HCP and Patient Congress Engagements, including KOL interactions with Invivyd leadership
Support and Execution of Strategic Marketing Initiatives
Proactive interactions with KOLs to validate and optimize brand strategies
Collaboration on the development of HCP and Patient marketing materials
Collaboration with local/ regional advocacy groups to develop and coordinate community engagement webinars

Required qualifications

7+ years of experience in pharmaceutical or biotechnology sales, or, with a focus on institutional customers
Field marketing or HCP marketing experience
In-depth knowledge of the healthcare industry, specifically institutional accounts
Proven track record of successfully managing Key Opinion Leaders and complex accounts
Proven record of meeting or exceeding business KPIs
Analytical mindset with the ability to interpret data, market trends, and customer insights
Experience working in Veeva and CRM systems and sales analytics tools
Ability to travel as required up to ~75% of the time to meet with customers and attend industry events
Must hold a current, valid state driver's license
Be able to pass a motor vehicle record (MVR) background check

Nice to have

Experience in Hematology, Transplant, Rheumatology, and Infectious Disease

About the company

Invivyd, Inc. is on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company uses a proprietary integrated technology platform to assess, monitor, develop, and adapt antibodies.